Salute e Benessere

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of…

Initiation of Phase 2 builds on data from a Phase 1 clinical trial evaluating the safety and tolerability of autogene cevumeran (BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and standard of care chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC)The Phase 2 trial is expected to enroll approximately 260 patients with PDAC at clinical trial sites initially in the United States, followed by Europe and Asia...
Nasdaq GlobeNewswire
19/10/2023

Personal Protective Equipment Market worth $69.4 billion by 2028 - Exclusive…

Browse in-depth TOC on "Personal Protective Equipment Market" Browse in-depth TOC on "Personal Protective Equipment Market" 218 – Tables 47 – Figures 250 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132681971 "Hand & Arm Protection was the largest type for personal protective equipment market in 2022 in terms of value." The personal protective equipment market is experiencing significant growth driven by many key…
PR Newswire
19/10/2023

Press Release: Sanofi delivers first medicines from Global Health Unit's Impact…

Sanofi delivers first medicines from Global Health Unit's Impact brand portfolioParis, October 19, 2023.Sanofi has delivered the first medicines from its Global Health Unit's not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis, a potentially lethal disease often underdiagnosed on the African continent. With this first shipment to...
Nasdaq GlobeNewswire
19/10/2023

oToBrite Launches a Comprehensive ADAS Product Portfolio for Heavy Commercial…

oToBrite BSIS can provide drivers the information signal of VRU, including pedestrians and two-wheelers within the blind spot area before making turn to reduce accidents. Besides, the product can expand MOIS by adding one additional camera to comply with UN R159 at the same time. With vision-AI technology, the product can handle complex urban traffic environments such as occluded VRU, a group of VRU, VRU near traffic signal pole, etc. oToBrite BSIS can provide drivers the information signal…
PR Newswire
19/10/2023

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical…

Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – Tampere University Hospital's (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and...
Nasdaq GlobeNewswire
19/10/2023

IMG Saxony-Anhalt: excellent medtech research cluster and innovative companies

The Magdeburg Port of Science is home to the Research Campus STIMULATE, for example, where more than 35 partners from industry, academia, and medicine are researching the medical technology of tomorrow in interdisciplinary teams, to improve the treatment of cancer and cardiovascular and neurological diseases, and with a focus on the development of imaging hardware and software. The Magdeburg Port of Science is home to the Research Campus STIMULATE, for example, where more than 35 partners…
PR Newswire
19/10/2023

Calliditas Therapeutics to Present Seven Abstracts at the American Society of…

"We take great pride in the robust clinical evidence we have gathered and look forward to presenting additional findings at ASN from our Phase 3 NefIgArd trial that further establish the beneficial effect of Nefecon on eGFR," said Richard Philipson, Chief Medical Officer at Calliditas. "These analyses, in addition to a presentation highlighting our new clinical program in the renal space targeting Alport syndrome, reinforce our dedication to expanding treatment options and…
PR Newswire
19/10/2023

New research highlights potential of iOnctura strategy combining autotaxin and…

Professor Davide Melisi said:"We have uncovered a new mechanism of action for autotaxin in resistance to TGF–β pathway inhibition. Data generated by our laboratory across in vitro and in vivo models and from human clinical samples support this important finding. These findings pave the way for clinical studies combining autotaxin inhibitors with TGF-β pathway inhibitors, addressing the fibrotic barrier that protects tumors and reversing immunosuppressive mechanisms encouraging the immune…
PR Newswire
19/10/2023

Silony Medical completes acquisition Centinel Spine's Global Fusion Business

Silony has been active in the US market since late 2018 - with this acquisition, Silony will capitalize on the great team and distribution network of the Centinel Fusion Portfolio to strengthen its position in the North American Spine Market to bring surgeons and their teams first in class spine fusion solutions that offer flexibility and freedom. Silony has been active in the US market since late 2018 - with this acquisition, Silony will capitalize on the great team and distribution network…
PR Newswire
19/10/2023

ASCENSIA DIABETES CARE POLAND EARNS GREAT PLACE TO WORK CERTIFICATION

The prestigious certification is awarded based on employee feedback about their experience working at Ascensia Diabetes Care Poland. The business received a high response rate from employees, with 91% participating in the survey, demonstrating significant internal engagement. The prestigious certification is awarded based on employee feedback about their experience working at Ascensia Diabetes Care Poland. The business received a high response rate from employees, with 91% participating in…
PR Newswire
19/10/2023

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own…

CEO Sengho Jeon expressed his excitement about the event, stating, "We are eagerly anticipating the opportunity to connect with our global partners, explore potential collaborations, and engage in ongoing discussions, with the expectation of entering into additional agreements this year. Our aim is to discuss how we can make our world healthier together, and foster new business prospects through this exhibition." CEOSengho Jeonexpressed his excitement about the event, stating, "We…
PR Newswire
19/10/2023

Basilea announces acquisition of novel clinical-stage antifungal for treatment…

New compound added to Basilea's clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025Upfront payments of USD 2 million Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, October 19, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered...
Nasdaq GlobeNewswire
19/10/2023

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth…

Groupsalesgrow by 1% 1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9% Pharmaceuticals Division salesgrow by 9%, driven by continued high demand for newer medicines Diagnostics Division's base businessincreases by 7%;overall divisional salesare down 18% due to a surge in demand for COVID-19 tests in 2022 Highlightsin the third quarter of 2023:...
Nasdaq GlobeNewswire
19/10/2023

Sequana Medical announces additional alfapump data supporting strong and durable…

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION19 October 2023, 07:00 am CEST One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12 monthsPatient preference study indicates that US patients have a strong preference for the alfapump vs large volume paracentesis i Matched interim analysis of patients from NACSELD iiregistry and POSEIDON pivotal cohort indicates that alfapump safety profile is comparable to...
Nasdaq GlobeNewswire
19/10/2023

ERS Genomics Limited ('ERS') completes licensing agreement with Syngene…

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent portfolio for this groundbreaking technology. DUBLIN,Oct. 18, 2023/PRNewswire/ -- ERS Genomics, co-founded by Dr.Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent...
PR Newswire
19/10/2023

Safety Meets Performance: xTool Launches World's First 40W Enclosed Class 1…

xTool S1 laser machine also features innovative Twin-point Positioning technology, a breakthrough offering precision akin to a coordinate system. This cutting-edge technology is integrated into the software, providing real-time display and enabling users to accurately determine the laser's position and set the material processing range. Additionally, the machine boasts Dynamic-focus Engraving, incorporating an Intelligent Focus System with real-time adjustments to the motorized Z-axis, ensuring…
PR Newswire
19/10/2023

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety…

The evaluable population was 28 patients (of a total 30 enrolled in the study). Patients received two (2) single intravenous (IV) infusions of TLX591, fourteen (14) days apart. Cohort 1 (5 patients) received a 27mCi dose followed by a 76 mCi dose for accuracy of biodistribution determination. Cohort 2 (23 patients) received two 76mCi doses. The evaluable population was 28 patients (of a total 30 enrolled in the study). Patients received two (2) single intravenous (IV) infusions of TLX591,...
PR Newswire
19/10/2023

Cholangiocarcinoma Treatment Drugs Market to Rise by 2032 | Key Analysis by…

Key Takeaways from the Cholangiocarcinoma Market Report Key Takeaways from the Cholangiocarcinoma Market Report Discover which therapies are expected to grab the major cholangiocarcinoma market share @Cholangiocarcinoma Market Report Cholangiocarcinoma Overview Cholangiocarcinoma, often referred to as bile duct cancer, is a rare but aggressive form of cancer that originates in the bile ducts. These are the thin tubes that carry bile from the liver to the small intestine...
PR Newswire
18/10/2023

Alkermes to Report Third Quarter Financial Results on October 25, 2023

About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham…
PR Newswire
18/10/2023

Pixium Vision announces the launch of a process to find buyers

Pixium Vision announces the launch of a process to find buyersParis, France, October 18, 2023- 19:30 (CET ) - Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX) (the " Company "), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces that a tender process ( appel d'offres ) for the purpose of finding buyers to acquire the Company's business will be published tomorrow...
Nasdaq GlobeNewswire
18/10/2023

Inside information: Bioretec estimates that the approval of the European market…

"Regulatory approvals are an integral and important part of a commercialization process in our industry. The approval processes and schedules of product registrations are always subject to uncertainty, and the company has limited opportunities to influence those. For our part, we will continue to work to obtain a market authorization and start commercialization in Europe", says Timo Lehtonen, CEO of Bioretec. "Regulatory approvals are an integral and important part of a…
PR Newswire
18/10/2023

Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome…

Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders. Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders. Using genetically-engineered mice, Dr. Zoghbi and her team learned that the brain is acutely...
PR Newswire
18/10/2023

Frost & Sullivan Recognizes Neuromod Devices with the 2023 New Product…

Neuromod has delivered a groundbreaking medical device and services that support healthcare professionals to achieve exceptional clinical outcomes for their tinnitus patients. The company's flagship product, the Lenire® device for tinnitus treatment, boosted Neuromod's market leadership further and clearly differentiated the company because of its superior design, unmatched reliability, and first-class quality. Lenire® combines acoustic and electrical intraoral stimulation by leveraging a…
PR Newswire
18/10/2023

Ramsay Sante : Annual Results at the end of June 2023

PRESS RELEASE Paris, 18 thOctober 2023 Annual results at the end of June 2023Group revenue increased by 9.3% to €4.7bn supported by positive activity volume growth in all geographies and recent acquisitions in the Nordic countries. Revenue growth on a like-for-like basis of 7.0%.Group EBITDA decreased by 5.6% to €621.4m, impacted by lower subsidies, high salary and procurement inflation and staff shortage challenges.Group share of net result after tax of €49...
Nasdaq GlobeNewswire
18/10/2023
Altri  Comunicati